Kodiak Sciences Inc. (KOD) Stock Analysis
Healthcare · Biotechnology · NasdaqGM
Kodiak Sciences Inc. (KOD) posted $0 in revenue for fiscal 2025, with a net loss of $229.97M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Kodiak Sciences Inc.
Kodiak Sciences Inc. has grown revenue from $0 to $0 over the last 10 fiscal years.
The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Kodiak Sciences Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Kodiak Sciences Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-17.13M | $-27.94M | $-41.44M | $-47.37M | $-133.10M | $-266.99M | $-333.82M | $-260.49M | $-176.21M | $-229.97M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
Source: Kodiak Sciences Inc. SEC filings (10-K).
Kodiak Sciences Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 19.2% over 4 years (51.8M → 61.8M) — existing holders' stakes are being diluted.
Explore 10 years of Kodiak Sciences Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track KOD in your portfolio →
Kodiak Sciences Inc. financial history by metric
About Kodiak Sciences Inc.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Kodiak Sciences Inc. — frequently asked questions
What is Kodiak Sciences Inc.'s revenue?
Kodiak Sciences Inc. (KOD) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Kodiak Sciences Inc. profitable?
No — KOD reported a net loss of $-229.97M in fiscal 2025.
What is KOD's P/E ratio?
Kodiak Sciences Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Kodiak Sciences Inc. have?
As of fiscal year 2025, KOD carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Kodiak Sciences Inc.'s market cap?
Kodiak Sciences Inc. (KOD) has a market capitalization of about $2.09B, based on the latest data in our nightly-refreshed cache.
When does Kodiak Sciences Inc.'s fiscal year end?
KOD's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Kodiak Sciences Inc.'s official SEC filings (10-K and 10-Q), covering 10 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.